Skip to main content

Table 3 The effect of L-NMMA on GFR and renal handling of sodium and potassium after six weeks of paricalcitol treatment in patients with stage III-IV CKD and albuminuria (n = 21)

From: Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial

  Baseline 30 min 60 min 90 min 120 min P Within P Between
GFR ( 51 Cr-EDTA clearance)
Placebo 26.3 ± 13.3 22.8 ± 10.9 24.2 ± 11.1 26.0 ± 11.7 27.8 ± 11.5 0.68 0.31
Paricalcitol 23.6 ± 11.5* 20.3 ± 9.7 22.5 ± 10.9 22.5 ± 12.0 23.9 ± 12.8 0.89
Urine output (ml/min)
Placebo 4.5 ± 2.1 3.1 ± 1.3 3.4 ± 1.2 3.6 ± 1.1 4.0 ± 1.8 0.02 0.15
Paricalcitol 3.4 ± 1.5* 2.4 ± 0.9 2.8 ± 1.2 3.1 ± 1.1 3.7 ± 1.5 0.01
Free water clearance (ml/min)
Placebo 1.7 ± 1.7 1.6 ± 1.4 1.1 ± 0.9 1.3 ± 0.9 1.5 ± 1.0 0.65 0.16
Paricalcitol 0.8 ± 1.0* 0.8 ± 1.0 0.7 ± 0.7 1.0 ± 0.9 1.3 ± 0.9 0.27
FE Na (%)
Placebo 5.9 ± 4.3 4.7 ± 3.4 4.4 ± 3.1 4.2 ± 2.8 4.1 ± 2.7 0.37 0.54
Paricalcitol 5.9 ± 4.5 4.4 ± 3.7 4.4 ± 3.4 4.6 ± 4.1 4.6 ± 4.0 0.73
FE K (%)
Placebo 85 ± 95 67 ± 70 62 ± 62 58 ± 51 55 ± 45 0.61 0.74
Paricalcitol 92 ± 96 71 ± 65 67 ± 58 66 ± 55 63 ± 50 0.63
u-AQP2 (ng/hr)
Placebo 99 ± 37 71 ± 29 77 ± 34 80 ± 37 87 ± 51 0.16 0.67
Paricalcitol 100 ± 35 71 ± 30 74 ± 29 75 ± 32 75 ± 31 0.03
u-ENaC γ (ng/hr)
Placebo 9.6 ± 7.7 - 8.8 ± 7.8 - 9.8 ± 9.0 0.92 0.32
Paricalcitol 10.3 ± 5.3 - 8.2 ± 2.3 - 8.8 ± 3.7 0.21
  1. Values are means ± SD. L-NMMA, NG-monomethyl-L-arginine; FENa, fractional excretion of sodium; FEK, fractional excretion of potassium; AQP2, aquaporin 2 channels; ENaCγ, gamma fraction of epithelial sodium channels. L-NMMA infusion was sustained for 60 minutes. Pwithin represents the probability of an effect of NOS inhibition after each treatment assessed by one-way ANOVA. Pbetween represents the probability that paricalcitol alters the response to L-NMMA assessed by a general linear model for repeated measures with treatment as factor.
  2. * = p < 0.05 vs. placebo at baseline.